image credit- shutterstock
AstraZeneca will invest $4.5 billion in its new manufacturing facility in Virginia, US, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments.
This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect jobs, powering economic growth and Virginia’s leadership at the forefront of life sciences innovation.
The manufacturing facility is expected to create 600 highly skilled jobs in Virginia including engineers, scientists, process facilitators which includes an additional 100 jobs as a result of the expansion. A further 3,000 jobs will be created to support the construction of the facility including engineers, skilled trades and construction workers. It will be at the forefront of technological innovation, leveraging AI, automation, and data analytics to optimise production.
The new facility will produce drug substance for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products.
The company has expanded the scope to also include state-of-the-art manufacturing for our leading antibody drug conjugate (ADC) cancer portfolio. Work will start immediately with the facility expected to be operational in the next four to five years. This investment will bring critical medicine manufacturing capabilities to the United States and offers assurance from a national security and health sovereignty perspective.
